Motivated by the AA proposal, we investigated a biofluid staging system defined by p-tau217, p-tau205 and NTA-tau as early, intermediate, and advanced stage fluid markers (respectively) of AD progression. The gene discussed is MAPT; the disease is Alzheimer disease.